• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    ProMIS Neurosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/12/25 7:37:22 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PMN alert in real time by email
    PROMIS NEUROSCIENCES INC._May 12, 2025
    0001374339false00013743392025-05-122025-05-12

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 12, 2025

    PROMIS NEUROSCIENCES INC.

    (Exact name of registrant as specified in its charter)

    ​

    Ontario, Canada

        

    001-41429

        

    98-0647155

    (State or other jurisdiction
    of incorporation)

     

    (Commission
    File Number)

     

    (IRS Employer
    Identification No.)

    ​

    ​

    Suite 200, 1920 Yonge Street,
    Toronto, Ontario

        

     

        

    M4S 3E2

    (Address of principal executive
    offices)

     

     

     

    (Zip Code)

    ​

    Registrant’s telephone number, including area code: (416) 847-6898

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of Each Class

        

    Trading Symbol(s)

        

    Name of Each Exchange on Which Registered

    Common Shares, no par value per share

    ​

    PMN

    The Nasdaq Capital Market

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

    Emerging growth company  ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    Item 2.02Results of Operations and Financial Condition

    On May 12, 2025, ProMIS Neurosciences Inc. (the "Company") issued a press release, which is available on its website (www.promisneurosciences.com under “Investors/Financial Results”), reporting its financial condition and financial results as of and for the three months ended March 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this report and is incorporated by reference into this Item 2.02.

    Item 9.01Financial Statements and Exhibits.

    (d) Exhibits

    ​

    ​

    ​

    Exhibit No.

        

    Description

    99.1

    ​

    Press Release dated May 12, 2025

    104

    ​

    Cover Page Interactive Data File (embedded within Inline XBRL document)

    ​

    ​

    ​

    ​

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

    ​

    ​

    ​

    PROMIS NEUROSCIENCES INC.

    ​

    ​

    ​

    Date: May 12, 2025

    By:

    /s/ Neil Warma

    ​

    ​

    Name: Neil Warma

    ​

    ​

    Title: Chief Executive Officer

    ​

    ​

    ​

    Get the next $PMN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PMN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PMN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Cashman Neil bought $14,595 worth of shares (15,000 units at $0.97) (SEC Form 4)

      4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

      2/12/25 5:21:35 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Shafmaster Madge K. bought $255,750 worth of shares (200,000 units at $1.28), increasing direct ownership by 2,400% to 208,333 units (SEC Form 4)

      4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

      9/24/24 6:56:35 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Gordon Michael S bought $116,880 worth of shares (93,223 units at $1.25) (SEC Form 4)

      4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

      9/18/24 4:15:05 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PMN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ProMIS Neurosciences Announces First Quarter 2025 Financial Results

      First Cohort Completed in PRECISE-AD Trial Evaluating PMN310 in Alzheimer's Disease  Six Month Interim Results Expected in 1H 2026 Topline Results Anticipated by end of 2026 CAMBRIDGE, Massachusetts, May 12, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD) and multiple system atrophy (MSA), today announced financial results for the first quarter ended March 31, 2025. "We made significant

      5/12/25 7:30:00 AM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

      Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer's Disease PRECISE-AD Six Month Interim Results Expected in 1H 2026 with Topline Results Anticipated by end of 2026 CAMBRIDGE, Massachusetts, March 31, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced financial results for the fiscal year end

      3/31/25 7:00:00 AM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference

      CAMBRIDGE, Massachusetts, March 24, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced plans to deliver virtual oral presentations at the 2025 Alzheimer's and Parkison's Disease (AD/PD) International Conference taking place in Vienna, Austria from April 1 - 4, 2025. The oral presentations are available on demand starting on Tuesday, April 1, 2025 at 7:00am C.E.T (2:00am E.T).

      3/24/25 7:00:00 AM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PMN
    SEC Filings

    See more

    $PMN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $PMN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form 10-Q filed by ProMIS Neurosciences Inc.

      10-Q - ProMIS Neurosciences Inc. (0001374339) (Filer)

      5/12/25 7:39:20 AM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProMIS Neurosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ProMIS Neurosciences Inc. (0001374339) (Filer)

      5/12/25 7:37:22 AM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by ProMIS Neurosciences Inc.

      DEFA14A - ProMIS Neurosciences Inc. (0001374339) (Filer)

      4/29/25 5:15:09 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Cashman Neil bought $14,595 worth of shares (15,000 units at $0.97) (SEC Form 4)

      4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

      2/12/25 5:21:35 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Principal Accounting Officer Milbury Max A.

      4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

      11/20/24 7:04:11 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Development Officer Kaplan Johanne

      4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

      11/20/24 7:03:06 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ProMIS Neurosciences Inc.

      SC 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)

      11/14/24 4:56:13 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ProMIS Neurosciences Inc.

      SC 13G - ProMIS Neurosciences Inc. (0001374339) (Subject)

      11/14/24 3:36:04 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ProMIS Neurosciences Inc.

      SC 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)

      11/6/24 4:15:57 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PMN
    Leadership Updates

    Live Leadership Updates

    See more
    • ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

      CAMBRIDGE, Massachusetts and TORONTO, Ontario, May 14, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update. "We continue to make significant progress as we are nearing completion of the Phase 1a single ascending dose clinical trial of PMN310 in Alzheimer's disease and remain on track to report top-

      5/14/24 4:01:00 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

      CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced financial results for the fiscal year ended December 31, 2023 and provided a corporate update. "I am pleased to have taken the helm of ProMIS at the beginning of 2024 and am proud of the meaningful progress the team has made to date as ProMIS made the transition to a clinical deve

      4/1/24 4:15:00 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProMIS Neurosciences, Inc. Announces Leadership Transition

      CAMBRIDGE, Massachusetts and TORONTO, Ontario, Jan. 03, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced a strategic leadership change. The Company's Board of Directors appointed Neil Warma, a highly-qualified biotechnology industry executive and ProMIS Board member, as interim Chief Executive Officer to succeed Gail Farfel, Ph.D., who has stepped down to pursue other opportunities. Mr. Warma's appoint

      1/3/24 7:00:00 AM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care